PolyPid Ltd (Nasdaq: PYPD), an Israel-based biopharmaceutical company, has enrolled and randomised the first patient in the SHIELD I (Surgical site Hospital acquired Infection prEvention with Local D-plex) trial of D-PLEX100, it was reported on Wednesday.
The trial is the firm's first of the two phase three clinical trials of its lead product candidate, D-PLEX100, intended for the prevention of post-abdominal surgery incisional infection (soft tissue). It is a multinational, multicentre, randomised, double blind Phase three trial aimed at evaluating the efficacy and safety of D-PLEX100 administered concomitantly with the Standard of Care, compared to a Standard of Care-treated control arm, for the prevention of post-abdominal surgery incisional infection.
The product is a novel product candidate aimed at offering local prolonged anti-bacterial activity directly at the surgical site to prevent surgical site infections. The Food and Drug Administration (FDA) has granted the product two Qualified Infectious Disease Product designations, which include prevention of sternal wound infection post-cardiac surgery, and the prevention of post-abdominal surgery incisional infection.
The trial will enrol a minimum of 616 patients, with a maximum of about 900 patients, as defined by the adaptive study design, in approximately 50 centres in the United States, Europe and Israel.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study